

1 **Screening of biofilm-producing genes from *Acinetobacter* isolates obtained from Covid-19**  
2 **patients in ICU hospital section**

3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
preprint

۲۰ **Abstract**

۲۱ Acinetobacter, recognized as a nosocomial pathogen, undergoes structural changes when exposed  
۲۲ to various antibiotics, rendering it relatively resistant and posing challenges in disease treatment.  
۲۳ This study aimed to identify two biofilm-related genes and assess the drug resistance profile of  
۲۴ clinical strains. Clinical isolates were collected from the ICU of Afzalipour Hospital in Kerman,  
۲۵ Iran, and phenotypically identified. Confirmation was achieved for 55 clinical Acinetobacter  
۲۶ isolates. Antibigram testing was conducted for meropenem, amikacin, ampicillin-sulbactam,  
۲۷ cefotaxime, levofloxacin, rifampin, and tigecycline antibiotics. Biofilm formation ability was  
۲۸ assessed using microtiter plates and crystal violet staining, followed by spectrophotometry at OD  
۲۹ 490 nm. PCR was employed to determine the frequency of *pslA* and *pelB* genes. Analysis revealed  
۳۰ that the highest age group affected was 1 to 15 years (19%), while the lowest was 26 to 35 years  
۳۱ (5%). The frequencies of *pslA* and *pelB* genes were 34.5% and 65.5%, respectively, and drug  
۳۲ resistance ranged from 72% to 100% for the mentioned antibiotics. Given the *pelB* gene's  
۳۳ approximately twofold higher frequency compared to *pslA*, it suggests that in most studied  
۳۴ isolates, *Psl* may often be disrupted or that intracellular c-di-GMP levels have significantly  
۳۵ increased.

۳۶ Keywords: Biofilms, *Acinetobacter*, Drug Resistance, Antibiotic, *pslA* and *pelB* genes

۳۷

۳۸

۳۹

۴۰

## 1. Introduction

The corona epidemic that started in the world in 2019 led to an increase in the number of patients in the ICU department of hospitals (1, 2). Corona virus caused many problems for patients due to the involvement of the respiratory system (1-4).

The corona pandemic caused a large number of people to be admitted to the intensive care units of hospitals. Due to the special closed system of these parts and the lack of proper air circulation, Spire equipment is a suitable place for the accumulation of commensal bacteria and the creation of biofilm (5, 6).

Biofilm is actually a collection of microbes that stabilize on a surface. Bacteria in biofilm structures have relationships with each other and their behavior is different from when they are alone. The resistance of bacteria to antimicrobial agents in the biofilm state is different from the planktonic state. Many genes are involved in the formation of biofilm, these genes act in a cascade manner and the activity of one gene depends on the activity of another gene (7).

In the biofilm structures, there are steps to form the biofilm structure, in which the initial attachment of the bacteria to the surface is done and the bacteria are colonized (8).

In the next stage, bacteria multiply on the surface and their number increases. And then they get trapped inside an extracellular matrix, which prevents the penetration of antimicrobial agents into the biofilm structure (9, 10).

*Acinetobacter* is a gram-negative bacterium without spores, which is one of the most important bacteria resistant to antimicrobial agents and antibiotics. These bacteria have a wide frequency in the intensive care units of the hospital and causes widespread problems (12-16).

٦٢ *Acinetobacter* biofilms have been studied to a lesser extent. The purpose of this research is to  
٦٣ investigate the effective genes in the production of *Acinetobacter* biofilm (18).

## ٦٤ **2. Materials and Methods**

### ٦٥ **2. 1. Isolation and Identification**

٦٦ In this research, 47 *Acinetobacter* strains were isolated from clinical samples collected from  
٦٧ Afzalipur Hospital, Kerman. Their initial identification was done by some biochemical tests such  
٦٨ as Gram staining, oxidase, catalase and etc(19).

### ٦٩ **2. 2. Antibiogram Test**

٧٠ The antibiotic resistance pattern of the collected strains was determined by standard methods. The  
٧١ disk diffusion method was used to measure the antimicrobial effect. Discs containing antibiotics  
٧٢ were placed on Mueller Hinton's medium, on which the bacteria had been previously cultured, and  
٧٣ kept at 35 degrees for 24 hours, and then the halo of non-growth was measured (20).

### ٧٤ **2. 3. Biofilm Assay**

٧٥ Microtiter plate method was used to measure the ability of isolated *Acinetobacter* strains to form  
٧٦ biofilm. In this method, the studied bacteria that had reached half McFarland turbidity were  
٧٧ cultured in a microplate containing Mueller Hinton Broth medium and incubated for 24 hours at  
٧٨ 37 degrees. After the incubation time, the contents of the plates were emptied and the biofilms  
٧٩ formed by the bacteria were stained with 1% crystal violet. According to the following formula,  
٨٠ the strength of the strains in biofilm formation was calculated. (21, 22, 23)

٨١ 
$$OD \leq OD_c = \text{not biofilm producer}$$

٨٢ 
$$OD_c < OD \leq (2 \times OD_c) = \text{weak biofilm}$$

83  $(2 \times OD_c) < OD \leq (4 \times OD_c) = \text{moderate biofilm}$

84  $(4 \times OD_c) \leq OD = \text{strong biofilm}$

85 **Equation 1:** Classification of composed biofilms based on OD.

#### 86 2.4. DNA Extraction and Polymerase Chain Reaction (PCR)

87 The DNA of studied strains were obtained using the genome extraction kit. Polymerase chain  
88 reaction was performed using special primers for two genes (*PelB*, *PslA*), the conditions of the  
89 reaction are given in the Table 1, finally, the PCR product was loaded on a 1% gel and observed  
90 with a UV device. (UVitec, Cambridge, UK).

91 **Table 1:** PCR methods

Gene	Primer	Product size (bp)	PCR program *	Ref
<i>PelB</i>	F: 5'- CGCCTGCTCTGGTTCTACAT -3' R: 5'- AGTCGTTGGGATTGGACTTG -3'	400	Initialization: 5 sec- 95 °C Denaturation: 30 sec- 95 °C	(25)
<i>PslA</i>	F: 5'- CACTGGACGTCTACTCCGACGATAT -3' R: 5'- GTTTCTTGATCTTGTGCAGGGTGTC -3'	163	Annealing: 45 sec- 51 °C Elongation: 45 sec- 72 °C	(25)
16S rRNA (Specific to <i>P. aeruginosa</i> )	F: 5'- CTACGGGAGGCAGCAGTGG -3' R: 5'- TCGGTAACGTCAAAACAGCAAAGT-3'	600	Final elongation: 5 sec- 95 °C	(25)

92 \*: The PCR program was performed for 35 cycles.

93

### 94 3. Results

#### 95 3.1. Antibioqram Test

96 The results of the antibiogram test are shown in Table (2). As can be seen in this table, there is  
97 resistance to most of the antibiotics mentioned in the table, and the highest resistance to Rifampin  
98 antibiotics and the lowest resistance to Ampicillin-Sulbactam


99 **Table 2:** Antibioqram test results (%).

Antibiotics	Sensitive	Intermediate	Resistance
Meropenem	0	0	100
Amikacin	0.93	0.93	98
Ampicillin-Sulbactam	0.93	28	71
Cefotaxime	0.93	0	99
Levofloxacin	0	0.93	99
Rifampin	0	0	100
Tigecycline	5	23	72

100

#### 101 3.2. Biofilm Assay

102 Figure 1 shows image of the biofilm created by *Acinetobacter* strains. This image is after coloring  
103 by Crystal Violet. As can be seen in this picture, 36 strains of *Acinetobacter* were strong biofilm  
104 forming, 13 strains were medium biofilm and 6 strains had low potential for biofilm formation.



105

106

**Fig 1:** Biofilm formation by *Acinetobacter* strains.

107

### **3.3. PCR and Gel Electrophoresis**

108

The results of the screening of biofilm producing genes are shown in Figure 2, which is actually

109




the product of PCR using gene-specific primers. As can be seen in this figure, 19 strains have PslA

110

gene and 36 strains have PelB gene, and in general, the frequency of these two genes is 34 and

111

65%, respectively.



112

113

114 **Fig 2:** PCR product by specific primers: A) Determination of PCR reaction specificity, column 1  
 115 of sterile distilled water as the negative control, column 2 of positive control, column 3 of  
 116 *Acinetobacter* gene, column 4 of the ladder. B) *PslA* and C) *PelB*.



#### 117 **4. Discussion**

118 *Acinetobacter*, known for its opportunistic nature and numerous virulence factors, has a significant  
119 capacity to form biofilms. These biofilms can diminish the effectiveness of antimicrobial drugs,  
120 leading to chronic infections. According to a study by Saxena et al. (2014), 80 *Acinetobacter*  
121 isolates were collected from patients with lower respiratory tract infections in India (6, 7). The  
122 findings, obtained through a method comparable to the current study, revealed high resistance rates  
123 to amoxiclav (97%) and levofloxacin (74%), while resistance to amikacin was notably lower at  
124 33% (26).

125 A study conducted in Iran on 55 clinical *Acinetobacter* isolates reported a resistance rate of 98%.  
126 The notable disparity in amikacin resistance between the clinical isolates from Iran and India might  
127 be explained by differences in local lifestyles and the varied hospital wards from which the samples  
128 were obtained. Additionally, the biofilm analysis of the 80 isolates from Lucknow, India, indicated  
129 that 20% formed strong biofilms, 21.25% moderate biofilms, and 58.75% weak biofilms (27).

130 In similar studies conducted in Iran, the current study observed the highest frequency of strong  
131 biofilm formation, with only 10.90% of the isolates demonstrating weak biofilm formation.  
132 According to Heydari and Eftekhar (2015), in their investigation of *Acinetobacter* isolates from a  
133 burn unit in Iran, 66.7% of the isolates formed strong biofilms, while 33.3% formed weak biofilms  
134 (28). Their findings also revealed that all biofilm samples tested positive, and 14% of the samples  
135 negative for biofilm formation possessed the PslA gene. In a recent study by Kamali et al. (2020),  
136 examining 80 *Acinetobacter* isolates, the biofilm formation ratios were reported as 16.25% strong,  
137 33.75% moderate, 33.75% weak, and 16.25% incapable of forming biofilms. Additionally, 12.5%  
138 of the isolates were resistant to amikacin. (29).

139 In *Acinetobacter*, genes associated with biofilm formation include *ppyR*, *pslA*, and *pelA*, along  
140 with genes related to alginate production such as *algD*, *algU*, and *algL*. Mucoid strains that  
141 overproduce alginate can facilitate lung colonization in cystic fibrosis (CF) patients, often leading  
142 to fatal outcomes (30, 31). Before mucoid strains appear, non-mucoid strains that produce Psl and  
143 Pel biofilms tend to colonize the patients' lungs. Strains that produce matrix IV result in stable  
144 rugose small-colony variants (RSCV), which are prolific producers of Pel and Psl. Generally,  
145 mutations that increase intracellular levels of c-di-GMP can boost the expression of Pel and Psl  
146 genes, leading to the RSCV phenotype (32, 33). This RSCV phenotype is also more resistant to  
147 antibiotics and the immune system. Notably, the RSCV phenotype was observed in 33 out of 86  
148 CF patients with *P. aeruginosa* over a two-year period. (34).

149 Cho et al. (2018) investigated 82 carbapenem-resistant *Acinetobacter* isolates from various  
150 hospital wards in South Korea and found that approximately 93% of the biofilm-forming isolates  
151 possessed the *PslA* gene. In contrast, the current study found a *PslA* gene presence of about 34.5%,  
152 although the initial screening of isolates was not based on carbapenem resistance.

153 Typically, when both Psl and Pel are present, Psl tends to dominate, with Pel having only a limited  
154 impact on biofilm phenotypes. However, in cases where the Psl operon is absent or disrupted, such  
155 as in PA14, or when c-di-GMP levels are significantly increased, Pel plays a more prominent role  
156 in biofilm formation. This study's findings indicated that the frequency of the *pelB* gene was about  
157 twice that of the *pslA* gene. Colvin et al. (2012) also studied the PAO1 strain, which mainly relies  
158 on Psl for biofilm formation, and reported that mutations in *psl* result in the formation of weak  
159 biofilms (35), which eventually strengthen after a prolonged period due to Pel rearrangement.  
160 Similarly, Emami et al. (2015) found that 70% of *Pseudomonas* isolates could form biofilms, with  
161 the *pslA* gene present in approximately 43% of them.(36, 37).

162 **5. Conclusion**

163 This study identifies the pel and psl genes as key contributors to the formation of strong, moderate,  
164 and weak biofilms in pathogenic *Acinetobacter* bacteria. The presence of these genes enhances the  
165 bacterium's pathogenicity and its resistance to antibiotics. Therefore, research aimed at inhibiting  
166 these two genes could not only reduce the biofilm-forming ability and proliferation of *Acinetobacter*  
167 but also improve the effectiveness of various antibiotics in treating diseases caused by this bacterium.

168 **Ethics Declarations**

169 **Competing Interests:** There are not any conflicts of interest among the authors.

170 **Funding:** Funding information: Not applicable

171 **Author contributions:**

172 **Data Availability:** Data will be available after publication

173 **Ethics Approval:** All authors approve the ethics in this study

174 **Acknowledgment:** Not applicable.

175

176

177

178

179

180 **References**

181

- 182 1. Al-Rashedi, N. A., Alburkat, H., Hadi, A. O., Munahi, M. G., Jasim, A., Hameed, A., ... & Smura,  
 183 T. (2022). High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in  
 184 Iraq, winter 2020–2021. *PLoS One*, 17(5), e0267295.
- 185 2. Qasemi A, Bayat Z, Akbari N, Babazadeh D. Bacterial Resistance of *Acinetobacter baumannii*:  
 186 A Global Concern. *Research in Biotechnology and Environmental Science*. 2022; 1(2): 36-42.
- 187 3. Bahrami Nejad Joneghani R, Bahrami Nejad Joneghani R, Dustmohammadloo H, Bouzari P,  
 188 Ebrahimi P, Fekete-Farkas M. Self-Compassion, Work Engagement and Job Performance among  
 189 Intensive Care Nurses during COVID-19 Pandemic: The Mediation Role of Mental Health and the  
 190 Moderating Role of Gender. *In Healthcare* 2023 Jun 29 (Vol. 11, No. 13, p. 1884). MDPI.
- 191 4. Salehinasab A, Sichani AR, Mousavi M, Bayat Z, Pezhhan A, Hussien BM, Ahmed M,  
 192 Hassanshahian M. Investigation of Microbial Biofilms during COVID-19 Pandemic: A  
 193 Bibliometric Analysis. *Iranian Red Crescent Medical Journal* 2023 Sep 1;25(9).
- 194 5. Al-Rashedi, N. A., Alburkat, H., Munahi, M. G., Jasim, A. H., Salman, B. K., Oda, B. S., ... &  
 195 Smura, T. (2022). *Genome Sequence of an Early Imported Case of SARS-CoV-2 Delta Variant (B.1.617.2 AY. 122) in Iraq in April 2021. Microbiology Resource Announcements, 11(11), e00977-22.*
- 196 6. Al-Rashedi, N. A., Munahi, M. G., & Ah ALObaidi, L. (2022). Prediction of potential inhibitors  
 197 against SARS-CoV-2 endoribonuclease: RNA immunity sensing. *Journal of Biomolecular*  
 198 *Structure and Dynamics*, 40(11), 4879-4892.
- 199 7. Hussain, S. ., Sheikh, N. ., Anjum, M. ., Raza, A. G. ., & Rizvi, R. . (2023). Mathematical  
 200 modelling of COVID-19 pandemic in Pakistan with optimal control. *Journal of Asian Scientific*  
 201 *Research*, 13(1), 28–44. <https://doi.org/10.55493/5003.v13i1.4721>
- 202 8. Luque- Ramos, L., Vilca, J. A., Pilco, A. V., & Cachicatari -Vargas, E. (2024). Events allegedly  
 203 attributable to vaccination and immunization of COVID-19 in people who received up to the third  
 204 dose, Tacna-Peru, 2022. *Nurture*, 18(1), 91–102. <https://doi.org/10.55951/nurture.v18i1.545>
- 205 9. Davoudi-Monfared E, Khaje-Mozafari J, Keramatinia A, Naimi E, Amiri P, Rahimpour E, et al.  
 206 A Review on Lifestyle Before and After COVID-19 Pandemic: Four Levels of Prevention:  
 207 Lifestyle before and after COVID-19 pandemic. *Int J Body Mind Cult*. 11(2).
- 208 10. Saberi-Hamedani M, Amiri P, Keramatinia A, Shahrbafe MA, Shekarriz-Foumani R. The  
 209 Prediction of Suicide Ideation Based on Perceived Social Support, Personality Traits, and Meaning  
 210 of Life in Medical Students during COVID-19 Pandemic: A Cross-Sectional Study: Suicide  
 211 ideation prediction in medical students. *Int J Body Mind Cult*. :272–281.
- 212 11. Hashemikamangar SS, Afshari A, Aghamir ZS, Kamali F. Impact of Oral Health Literacy and  
 213 COVID-19 Induced Anxiety on Dentistry Visits of the Iranian Public: COVID-19 induced anxiety  
 214 and dentistry visits. *Int J Body Mind Cult*. :366–373.
- 215 12. Motavaselian M, Farrokhi M, Jafari Khouzani P, et al. Diagnostic Performance of Ultrasonography  
 216 for Identification of Small Bowel Obstruction; a Systematic Review and Meta-analysis. *Arch Acad*  
 217 *Emerg Med*. 2024; 12(1): e33. <https://doi.org/10.22037/aaem.v12i1.2265>.
- 218 13. Shamabadi, A., Karimi, H., Arabzadeh Bahri, R., Motavaselian, M., & Akhondzadeh, S. (2024).  
 219 Emerging drugs for the treatment of irritability associated with autism spectrum disorder. *Expert*  
 220 *Opinion on Emerging Drugs*, (just-accepted).
- 221 14. I. Saadi, M. I., Nikandish, M., Ghahramani, Z., Valandani, F. M., Ahmadyan, M., Hosseini, F., ...  
 222 & Ramzi, M. (2023). miR-155 and miR-92 levels in ALL, post-transplant aGVHD, and CMV:  
 223 possible new treatment options. *Journal of the Egyptian National Cancer Institute*, 35(1), 18.
- 224 15. I. Irvani Saadi, M., Jiang, M., Banakar, M., Mardani Valandani, F., Ahmadyan, M., Rostamipour,  
 225 H. A., ... & Hosseini, F. (2023). Are the Costimulatory Molecule Gene Polymorphisms (CTLA-4)

- 228 Associated With Infection in Organ Transplantation? A Meta-Analysis. *Cell Transplantation*, 32,  
 229 09636897231151576.
- 230 16. I. Khalafi-Nezhad, A., Saadi, M. I., Noshadi, N., Jalali, H., Ahmadyan, M., Kheradmand, N., ...  
 231 & Hamidieh, A. A. (2022). Change in Programmed Death-1 and Inducible Costimulator  
 232 Expression in Patients with Acute Myeloid Leukemia Following Chemotherapy and Its  
 233 Cytogenetic Abnormalities. *Galen Medical Journal*, 11, e2394-e2394.
- 234 17. HJazi, A. (2023). The effects of Capsicum annum supplementation on lipid profiles in adults with  
 235 metabolic syndrome and related disorders: A systematic review and meta- analysis of randomized  
 236 controlled trials. *Phytotherapy Research*.
- 237 18. Al-Obaidi ZMJ, Hussain YA, Ali AA, Al-Rekabi MD. The influence of vitamin-C intake on blood  
 238 glucose measurements in COVID-19 pandemic. *J Infect Dev Ctries*. 2021 Mar 7;15(2):209-213.  
 239 doi: 10.3855/jidc.13960. PMID: 33690202.
- 240 19. Lattef Ismaeel, Z. A. (2024). Anatomical study with antibacterial and antibiofilm effects of  
 241 *Erodium cicutarium* (L.) L'H phenolic roots extract. *Caspian Journal of Environmental Sciences*,  
 242 22(1), 137-146. doi: 10.22124/cjes.2023.6762
- 243 20. H. Ahmed, M., K. Resen, A., & S. AL-Niaem, K. (2022). Effects of antibiotic residues on some  
 244 health parameters of Planiliza abu H. in Shatt Al-Arab, Southern Iraq. *Caspian Journal of*  
 245 *Environmental Sciences*, 20(5), 1059-1068. doi: 10.22124/cjes.2022.6080
- 246 21. Obaid, R. F., Kadhimi Hindi, N. K., Kadhumi, S. A., jafaar alwaeli, L. A., & Jalil, A. T. (2022).  
 247 Antibacterial activity, anti-adherence and anti-biofilm activities of plants extracts against  
 248 *Aggregatibacter actinomycetemcomitans*: An in vitro study in Hilla City, Iraq. *Caspian Journal of*  
 249 *Environmental Sciences*, 20(2), 367-372. doi: 10.22124/cjes.2022.5578
- 250 22. Stepanović S, Vuković D, Dakić I, Savić B, Švabić-Vlahović M. A modified microtiter-plate test  
 251 for quantification of staphylococcal biofilm formation. *Journal of microbiological methods*.  
 252 2000;40(2):175-9.
- 253 23. Garcia KCdOD, de Oliveira Corrêa IM, Pereira LQ, Silva TM, Mioni MdSR, de Moraes Izidoro  
 254 AC, et al. Bacteriophage use to control *Salmonella* biofilm on surfaces present in chicken  
 255 slaughterhouses. *Poultry science*. 2017;96(9):3392-8.
- 256 24. Sekiguchi J-I, Asagi T, Miyoshi-Akiyama T, Kasai A, Mizuguchi Y, Araake M, et al. Outbreaks  
 257 of multidrug-resistant *Pseudomonas aeruginosa* in community hospitals in Japan. *Journal of*  
 258 *clinical microbiology*. 2007;45(3):979-89.
- 259
- 260 25. Nikbakht, G. Novel Insights into Infection and immunity. *Iranian Journal of Veterinary Medicine*,  
 261 2022; 16(2): 99-100. doi: 10.22059/ijvm.2022.337927.1005234
- 262
- 263
- 264
- 265
- 266

۲۶۷

۲۶۸

Preprint